OptimizeRx (NASDAQ:OPRX) Price Target Raised to $14.00 at JMP Securities

OptimizeRx (NASDAQ:OPRX - Get Free Report) had its price objective hoisted by analysts at JMP Securities from $11.00 to $14.00 in a report released on Tuesday,Benzinga reports. The brokerage presently has a "market outperform" rating on the stock. JMP Securities' price objective would suggest a potential upside of 22.06% from the company's current price.

Separately, B. Riley upgraded OptimizeRx to a "strong-buy" rating in a research report on Wednesday, March 12th. Three equities research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company's stock. Based on data from MarketBeat, OptimizeRx currently has an average rating of "Moderate Buy" and a consensus target price of $9.81.

OptimizeRx Trading Up 24.7%

Shares of OPRX stock traded up $2.27 on Tuesday, hitting $11.47. The company had a trading volume of 717,285 shares, compared to its average volume of 272,152. The firm has a market cap of $212.11 million, a P/E ratio of -8.62 and a beta of 1.28. OptimizeRx has a twelve month low of $3.78 and a twelve month high of $14.13. The stock's 50-day moving average is $8.23 and its two-hundred day moving average is $6.34. The company has a debt-to-equity ratio of 0.29, a quick ratio of 3.23 and a current ratio of 3.23.

OptimizeRx (NASDAQ:OPRX - Get Free Report) last announced its quarterly earnings results on Monday, May 12th. The company reported $0.08 EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.19. The business had revenue of $21.93 million during the quarter, compared to analyst estimates of $18.69 million. OptimizeRx had a negative net margin of 27.41% and a negative return on equity of 4.92%. On average, equities research analysts anticipate that OptimizeRx will post -0.33 earnings per share for the current fiscal year.

Insider Activity at OptimizeRx

In other OptimizeRx news, Director James Paul Lang purchased 321,408 shares of the firm's stock in a transaction on Friday, March 14th. The stock was bought at an average cost of $7.60 per share, for a total transaction of $2,442,700.80. Following the completion of the purchase, the director now owns 389,452 shares in the company, valued at $2,959,835.20. This represents a 472.35% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 6.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On OptimizeRx

A number of institutional investors have recently bought and sold shares of OPRX. Whetstone Capital Advisors LLC acquired a new position in shares of OptimizeRx during the 4th quarter worth approximately $6,563,000. Royce & Associates LP acquired a new position in OptimizeRx during the fourth quarter worth about $5,198,000. Blair William & Co. IL grew its stake in OptimizeRx by 4.9% during the 1st quarter. Blair William & Co. IL now owns 631,031 shares of the company's stock valued at $5,465,000 after acquiring an additional 29,648 shares in the last quarter. Kennedy Capital Management LLC raised its holdings in OptimizeRx by 57.8% in the 4th quarter. Kennedy Capital Management LLC now owns 594,000 shares of the company's stock valued at $2,887,000 after acquiring an additional 217,676 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its stake in OptimizeRx by 9.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 444,167 shares of the company's stock worth $2,159,000 after purchasing an additional 39,740 shares in the last quarter. 76.47% of the stock is owned by hedge funds and other institutional investors.

OptimizeRx Company Profile

OptimizeRx Corporation, a digital health technology company, enables care-focused engagement between life sciences organizations, healthcare providers, and patients at critical junctures throughout the patient care journey. It offers various tech-enabled marketing solutions through its Artificial Intelligence-generated Dynamic Audience and Activation Platform, which enables customers to execute traditional marketing campaigns on its proprietary digital point-of-care network, as well as dynamic marketing campaigns that optimize audiences in real time to increase the value of treatment information for healthcare professionals and patients in response to clinical care events.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.